Daniel E. Benjamin Ph.D.
Daniel E. Benjamin Ph.D. is the Chief Executive Officer (CEO) of our company. With his extensive knowledge and experience, he leads the organization in setting strategic goals and implementing effective business strategies. He oversees the overall operations of the company, including financial performance, resource allocation, and risk management. Under his leadership, the company has achieved significant growth and success.
Dr Benjamin's graduate studies began in Prof. Harbans Lal's Lab in the department of pharmacology at University of North Texas Health Sciences Center. The department focused on Alzheimer’s disease and cognitive. Harbans Lal was one of the first investigators to test for a role of autoimmunity in age-related cognitive decline. This training occurred at the dawn of Alzheimer’s research, and taught that extreme risk can result in substantial reward. In addition to the core knowledge of pharmacodynamics and pharmacokinetics, Dr. Benjamin learned neuroanatomy and neurocircuitry in depth, as well as the logical basis and scientific precedents that allowed for solid functional conclusions on the neuroanatomical basis of physiology. Dr. Benjamin was the recipient of a competitive award from American Cyanamid Corporation to study the neuropharmacology and molecular biology of serotonin receptors. At Cascade, we are currently studying the role of complement in Renal disease, Schizophrenia, and Alzheimer’s disease and developing a gene therapy technology to deliver our complement depleting protein.
B. Positions and Honors.
Chief Executive Officer, Cascade Biotechnology Inc. 2015-present
Chief Executive Officer, Chief Scientist, Cenoxsys Corporation, Princeton, NJ 2009-Present
Chief Scientific Officer, AlsGen Inc. Princeton, NJ, 2004-2009
Manager, High Throughput Screening, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 2002-2005
Director, High Throughput Screening, FMC Corporation, Princeton, NJ 2001-2002
Star Award for Innovation, Comet Award for Project Management
Director, Pharmacology, Neuronyx Inc. Malvern, PA, 2000-2001
Principal Consulting Scientist, Johnson & Johnson, Spring House, PA 1995-2000
Assistant Professor, Rutgers University, Piscataway, NJ 1992-1998
Postdoc, Rutgers University, Piscataway, NJ, 1990-1992 National Research Service Award, NIAAA
C. Contributions to Science
Over the course of 30 years in science I have published over 100 papers and abstracts and received substantial funding from corporate sources, foundation sources and NIH. My dissertation work had some of the seminal studies on 5-HT1A agonists and anxiety, and the regulation of the 5-HT2A receptor. I was a participant in the first 5-HT2A knockout mouse studies and conducted the first antisense knockdown of the 5-HT2A receptor and OFQ opioid-like receptor as a professor at Rutgers. At Johnson & Johnson I developed their program in nvCJD and patented a new screen for protein aggregation that helped drive the ABeta aggregation program. We also did extensive work in Parkinson’s disease and Alpha Synuclein aggregation. Currently, we are working in the area of complement immune function.
D. Additional Information: Research Support and/or Scholastic Performance
I am currently supported by NIH (1R43NHL139170-01A1), private equity, a consultation practice, and corporate finance activities.
